• 1. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 2. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 3. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 4. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

4-Chloro-1H-pyrrolo[2,3-B]pyridine-2-carboxylic acid (CAS No. 1211583-37-7): A Comprehensive Overview

4-Chloro-1H-pyrrolo[2,3-B]pyridine-2-carboxylic acid (CAS No. 1211583-37-7) is a versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique structural features, has shown promising potential in various therapeutic applications, particularly in the development of novel drugs targeting specific biological pathways.

The chemical structure of 4-Chloro-1H-pyrrolo[2,3-B]pyridine-2-carboxylic acid is composed of a pyrrolo[2,3-b]pyridine core with a chloro substituent at the 4-position and a carboxylic acid group at the 2-position. This configuration imparts the molecule with distinct physicochemical properties, making it an attractive scaffold for drug design and synthesis. The presence of the chloro substituent enhances the lipophilicity of the molecule, which can improve its membrane permeability and bioavailability.

Recent studies have highlighted the biological activities of 4-Chloro-1H-pyrrolo[2,3-B]pyridine-2-carboxylic acid. For instance, a study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits potent inhibitory activity against specific kinases, which are key enzymes involved in cell signaling pathways. This property makes it a valuable lead compound for the development of targeted therapies for diseases such as cancer and inflammatory disorders.

In addition to its kinase inhibitory activity, 4-Chloro-1H-pyrrolo[2,3-B]pyridine-2-carboxylic acid has been investigated for its potential as an antiviral agent. Research conducted by a team at the National Institutes of Health (NIH) showed that this compound can effectively inhibit the replication of certain RNA viruses, including influenza and coronaviruses. The mechanism of action involves interfering with viral RNA synthesis and assembly processes, thereby reducing viral load and mitigating disease severity.

The synthetic accessibility of 4-Chloro-1H-pyrrolo[2,3-B]pyridine-2-carboxylic acid is another factor contributing to its appeal in pharmaceutical research. Various synthetic routes have been developed to produce this compound efficiently and cost-effectively. One notable method involves a multi-step synthesis starting from commercially available starting materials, such as 4-chloropyrrole and pyridine derivatives. These synthetic strategies not only facilitate large-scale production but also allow for the introduction of functional groups that can enhance the pharmacological properties of the final product.

The pharmacokinetic profile of 4-Chloro-1H-pyrrolo[2,3-B]pyridine-2-carboxylic acid has been extensively studied to optimize its therapeutic potential. Preclinical studies have shown that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties. It has good oral bioavailability and a reasonable half-life, which are crucial parameters for developing orally administered drugs. Furthermore, it demonstrates low toxicity in animal models, suggesting a favorable safety profile.

Clinical trials are currently underway to evaluate the efficacy and safety of 4-Chloro-1H-pyrrolo[2,3-B]pyridine-2-carboxylic acid-based drugs in human subjects. Early-phase trials have shown promising results, with patients experiencing significant improvements in disease symptoms and quality of life. These findings have spurred further investment in clinical development programs aimed at bringing these compounds to market.

In conclusion, 4-Chloro-1H-pyrrolo[2,3-B]pyridine-2-carboxylic acid (CAS No. 1211583-37-7) represents a promising lead compound in the field of medicinal chemistry and pharmaceutical research. Its unique structural features, combined with its diverse biological activities and favorable pharmacokinetic properties, make it an attractive candidate for the development of novel therapeutics targeting various diseases. Ongoing research and clinical trials are expected to further elucidate its potential and pave the way for its widespread use in clinical practice.

• 136818-50-3(1H-Pyrrolo[2,3-b]pyridine-2-carboxylic Acid)
• 215523-34-5(1,8-Naphthyridine-2-carboxylic acid)
• 1196151-72-0(Ethyl 4-chloro-1H-pyrrolo[2,3-b]pyridine-2-carboxylate)
• 913181-73-4(1H-Pyrrolo[2,3-b]pyridine-2-carboxylic acid hydrochloride)
• 871583-23-2(Methyl 4-chloro-1H-pyrrolo[2,3-b]pyridine-2-carboxylate)
• 800401-84-7(5-Chloro-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid)
• 800402-07-7(6-Chloro-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid)
• 898746-35-5(1H-Pyrrolo[2,3-b]pyridine-6-carboxylic acid)
• 952182-19-3(Methyl 5-chloro-1H-pyrrolo[2,3-b]pyridine-2-carboxylate)
• 1204475-64-8(1H-Pyrrolo[2,3-b]pyridine-2-carboxylic acid, 3-chloro-)